Research programme: obesity therapeutic - BioLineRx
Alternative Names: BL-3020Latest Information Update: 03 Mar 2010
Price :
$50 *
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioLineRx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 20 Jul 2006 Preclinical trials in Obesity in Israel (PO)